<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408120</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00078695</org_study_id>
    <nct_id>NCT02408120</nct_id>
  </id_info>
  <brief_title>Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes</brief_title>
  <official_title>Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether using extra doses of aspart insulin to correct
      blood sugars before meals improves the care of patients with type 2 diabetes in the hospital
      who are already receiving the standard of care treatment with glargine and aspart insulin
      injections to control blood sugar levels. Studies done in the past indicate that blood sugar
      levels are controlled on the standard treatment of insulin and that most patients do not need
      the small extra dose of insulin at bedtime. The investigators want to test if there is any
      benefit to giving patients extra doses of insulin during the day to correct the high blood
      sugars.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of patients with Type 2 diabetes involves treatment with two different types
      of insulin injections to control blood sugar levels. The doses of the two types of insulins,
      glargine insulin and aspart insulin are adjusted daily through the hospital stay based on
      blood sugar levels. Many times, in addition to glargine and aspart insulin at meals,
      additional small doses of aspart insulin are given to correct high blood sugar levels. It has
      not been determined if using these extra doses of aspart insulin to correct blood sugars
      before meals improves care of the patients. Studies done in the past indicate that blood
      sugar levels are well controlled on the standard treatment of the two insulins and that most
      patients do not need the small extra dose of insulin at bedtime. This study will test if
      insulin supplementation improves glycemic control and prevents hypoglycemia in insulin
      treated patients with type 2 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean daily blood glucose levels</measure>
    <time_frame>Screening, 5 days (average time of discharge from the hospital)</time_frame>
    <description>Blood glucose (BG) will be measured at screening and at the time of discharge in patients receiving insulin supplementation for correction of hyperglycemia (BG &gt;140 mg/dL) compared to those without insulin supplementation using a glucose meter. Change is the difference between the discharge blood glucose and screening blood glucose. Subjects that receive insulin supplementation for correction of severe hyperglycemia (BG &gt;260 mg/dL) are excluded from this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose levels before meals</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed prior to each meal using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose levels at bedtime</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed at bedtime using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose levels at 3:00 AM</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed at 3:00 AM using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of occurrences of hypoglycemia (blood glucose levels &lt; 70 mg/dL) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperglycemia</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of occurrences of hyperglycemia (blood glucose levels &gt; 260 mg/dL) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood glucose readings within 100-140 mg/dL range</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of blood glucose readings that are in the target range of 100-140 mg/dL will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of days of hospital stay</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The average number of days in the hospital for subjects will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The total number of subject deaths during hospital stay will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects that experienced hospital complications</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The total number of subjects in which hospital complications occurred prior to discharge will be recorded. These complications will mainly be cases of nosocomial infections, pneumonia, bacteremia, respiratory failure, and acute kidney injury [rise of serum creatinine &gt;0.5 mg/dL (or 50%) of baseline value]. Nosocomial infections will be diagnosed based on standardized Centers for Disease Control (CDC) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Symptom Assessment Scores</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The typical symptoms of hypoglycemia,e.g. sweating, tremulousness, hunger, and/or dizziness, loss of consciousness or other major alteration of mental status will be assessed using the Hypoglycemia Symptom Score Questionnaire post event. The score for each item on the Stanford hypoglycemia questionnaire ranges from 0-7. Higher total scores indicate more hypoglycemic symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is &gt;180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG &lt;70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Lantus (glargine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is &gt;180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG &lt;70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplemental insulin aspart</intervention_name>
    <description>Insulin aspart will be administered following the supplemental insulin scale protocol.
For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:
BG &gt;141-180 mg/dL; 2-4 units of insulin aspart
BG between 181-220 mg/dL; 3-6 units of insulin aspart
BG between 221-260 mg/dL; 4-8 units of insulin aspart
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG &gt; 400 mg/dL; 8-16 units of insulin aspart
For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG &gt; 400 mg/dL; 8-16 units of insulin aspart</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects admitted to the hospital with acute or chronic medical illnesses or for
             elective and emergency surgical illness or trauma

          2. Known history of Type 2 diabetes mellitus for &gt;3 months

          3. Treated with either diet alone, any combination of oral antidiabetic agents,
             non-insulin injectables or insulin therapy

          4. Blood glucose levels between &gt;140 mg and &lt;400 mg/dL without laboratory evidence of
             diabetic ketoacidosis

        Exclusion Criteria:

          1. Hyperglycemia without a history of diabetes

          2. Subjects with acute critical illness admitted to the ICU or expected to require ICU
             admission

          3. Subjects receiving continuous insulin infusion

          4. Clinically relevant hepatic disease

          5. Corticosteroid therapy

          6. Serum creatinine â‰¥ 3.5 mg/dL and/or glomerular filtration rate (GFR) &lt;30

          7. Subjects unable to sign consent

          8. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priyathama Vellanki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priyathama Vellanki, MD</last_name>
    <phone>(404) 778 1687</phone>
    <email>priyathama.vellanki@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priyathama Vellanki, MD</last_name>
      <phone>404-778-1687</phone>
      <email>priyathama.vellanki@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyathama Vellanki, MD</last_name>
      <phone>404-778-1687</phone>
      <email>priyathama.vellanki@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Priyathama Vellanki</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

